

# NATIONAL HEPATITIS B & C TRAINING PROGRAM and TREATMENT UPDATE 2018

July 28, 2018

**San Diego Marriott La Jolla**  
La Jolla, CA

September 8, 2018

**Sheraton Los Angeles San Gabriel**  
Los Angeles, CA

September 29, 2018

**Oakland Marriott City Center**  
Oakland, CA

October 6, 2018

**Sheraton Universal Hotel**  
Universal City, CA

October 20, 2018

**Hyatt Regency Sacramento**  
Sacramento, CA

October 20, 2018

**Irvine Marriott**  
Irvine, CA

## Course Overview

The Scripps National Hepatitis B & C Training Program and Treatment Update will contribute towards increasing the number of health care practitioners educated on the prevalence of chronic viral hepatitis, as well as those properly preventing, diagnosing, treating, and/or referring patients with chronic illness therefore contributing towards prevention of new cases, and improving management of already infected patients.

# NATIONAL HEPATITIS B & C TRAINING PROGRAM and TREATMENT UPDATE 2018

## Accreditation

### Physicians

Scripps Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Scripps Health and SC Liver Research Consortium. Scripps Health is accredited by the ACCME to provide continuing medical education for physicians.

Scripps Health designates this live activity for a maximum of **7 AMA PRA Category 1 Credit(s)<sup>TM</sup>**. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**About SC Liver Research Consortium (SCLRC)** is an organization of physicians specializing in hepatology and gastroenterology clinical research. Our mission is to team research sponsors and our network of over 100 research sites together to provide faster, higher-quality research results compared to the “conventional” sponsor-site arrangement. We provide access to our scientific expertise in study design, efficient site selection, streamlined contract and budget negotiations, and management assistance throughout the clinical trial. [www.scliver.com](http://www.scliver.com)

### About Scripps

Scripps Health, a nonprofit health care system based in San Diego, California, includes more than 2,600 affiliated physicians and over 13,000 employees at five acute-care hospital campuses, home health care services and a network of clinics, physician offices and outpatient centers. Scripps is committed to contributing to the future of medicine through its clinical research trials, graduate medical education and continuing medical education programs. More information can be found at [www.scripps.org](http://www.scripps.org).

## Educational Objectives

**After attending this live activity, participants should be able to:**

- Discuss the prevalence and incidence of acute and chronic hepatitis B and hepatitis C both in the general US population and in at-risk populations.
- Review the history, epidemiology, demographics, natural history, histology, immunology and patho physiology of the viral infection.
- Discuss state-of-the-art diagnostic and treatment guidelines for both hepatitis B and C.
- Formulate and/or implement strategies for preventing, diagnosing, treating, and/or referring patients with HBV and/or HCV.
- Evaluate the multidisciplinary team approach to care of patients with hepatitis B and C.
- Establish a local network of practitioners for information sharing, referrals, etc.
- Improve the health of patients infected with the HBV and/or HCV virus.

### Commercial Support

This course is supported, in part, by educational grants from industry, in accordance with ACCME accreditation Standards for Commercial Support. Appropriate acknowledgement will be given to all supporters at the time of the educational activity.

# NATIONAL HEPATITIS B & C

## TRAINING PROGRAM and TREATMENT UPDATE 2018

July 28, 2018

San Diego Marriott La Jolla  
La Jolla, CA

September 8, 2018

Sheraton Los Angeles San Gabriel  
Los Angeles, CA

September 29, 2018

Oakland Marriott City Center  
Oakland, CA

October 6, 2018

Sheraton Universal Hotel  
Universal City, CA

October 20, 2018

Hyatt Regency Sacramento  
Sacramento, CA

October 20, 2018

Irvine Marriott  
Irvine, CA

## Hepatitis C

We will review the virology, genotypes, modes of infection of HCV and characteristics of the clinical illness caused by acute and chronic infections. Birth-cohort screening will be outlined. Tests for HCV, including PCR assays and genotyping, non-invasive testing for fibrosis, interpretations and indications for liver biopsies and the natural history of the disease will all be discussed. We will show how to initiate and monitor patients during treatment with all-oral antiviral treatments for hepatitis C, manage drug-drug interactions and deal with various patient populations including pre- and post-liver transplant, HIV-coinfected and end-stage renal disease patients. We will summarize the latest AASLD/IDSA guidelines using all-oral direct acting antiviral regimens for HCV.

- 7:30 a.m. Registration, Breakfast and View Exhibits
- 8 a.m. **Review of Viral Hepatitis, Discovery of HCV and Natural History**
- 8:50 a.m. **Diagnostic Testing, Screening, Histology, Cirrhosis and Liver Biopsy**
- 9:45 a.m. Break & View Exhibits
- 10:15 a.m. **Antiviral Therapies**
- 11 a.m. **Updated Data from EASL 2018**
- 11:30 a.m. **Clinical Case Studies: HCV**

## Hepatitis B

We will summarize the history and discovery of HBV infection, discuss the modes of infection and prevalence of disease, and differentiate between acute and chronic infections. We will discuss protective antibodies, vaccination, complications of cirrhosis and hepatocellular carcinoma, tests for HBV, including PCR assays, genotyping and mutation analysis. We will include the latest AASLD guidelines for diagnosis, screening and treatment of chronic hepatitis B using nucleoside and nucleotide analogues for the treatment of chronic HBV including entecavir, TAF (tenofovir alafenamide), pegylated interferons and combinations of these regimens. We will also discuss new curative therapies for HBV in early development.

- 12:30 p.m. Lunch & View Exhibits
- 12:40 p.m. **Lunch Symposium: MAVYRET: Clinical Data Including Real World Evidence Non-CME Activity Hosted by AbbVie**
- 1:20 p.m. Break & View Exhibits
- 1:30 p.m. **Diagnostic Testing, Liver Biopsy, Cirrhosis and Hepatocellular Carcinoma**
- 2 p.m. **Anti-viral Therapies for HBV**
- 2:40 p.m. Break & View Exhibits
- 3 p.m. **Reactivation of Chronic HBV**
- 3:30 p.m. **Hepatitis B: The Slow March Towards a Cure**
- 4 p.m. **Case Studies in Hepatitis B**
- 5 p.m. Final Adjournment

### San Diego

**Paul Pockros, MD**  
Scripps Clinic  
La Jolla, California

### Catherine Frenette, MD

Scripps Clinic  
La Jolla, California

### Los Angeles

**Myron Tong, MD**  
University of California, Los Angeles  
Los Angeles, California

### Sammy Saab, MD

University of California, Los Angeles  
Los Angeles, California

### Oakland

**Paul Kwo, MD**  
Stanford University  
Stanford, California

### Alexander Monto, MD

University of California, San Francisco  
San Francisco, California

### Universal City

**Steven Han, MD**  
University of California, Los Angeles  
Los Angeles, California

### Jeff Kahn, MD

University Southern California  
Los Angeles, California

### Sacramento

**Paul Kwo, MD**  
Stanford University  
Stanford, California

### Robert Gish, MD

Stanford University  
Stanford, California

### Irvine

**John Hoefs, MD**  
University of California, Irvine  
Irvine, California

### Ke-Qin Hu, MD

University of California, Irvine  
Irvine, California

**Faculty Disclosure:** In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity.

**REGISTER ONLINE:** [www.scripps.org/hepbc](http://www.scripps.org/hepbc)

**Questions: Scripps Conference Services & CME | 858-678-6400 | [med.edu@scrippshealth.org](mailto:med.edu@scrippshealth.org)**

## REGISTRATION

**Includes:** Course tuition, access to online conference materials, internet in meeting space, breakfast, breaks and lunch

**Does not include:** Travel costs, lodging and parking

	Pre-Registration	Onsite Registration
<b>Registration Fees</b>	<b>\$110</b>	<b>\$125</b>
	Ends Tuesday prior to program date	Begins Wednesday prior to program date

## Attendance Policies

### Registration Confirmation

A confirmation letter will be e-mailed to you upon receipt of the conference registration form and payment. If you have not received it within two weeks, please contact the Scripps Conference Services & CME office.

### Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$25 processing fee, if your cancellation is received in writing no later than one week prior to the conference date. Attendee substitutions are allowed, but notification must be made in writing within one week of conference date. After this date, under no circumstances will refunds, credits, or substitutions be granted. No refunds or credits will be given to "no shows."